GANESH A. KOLUMAM,MONICA KONG BELTRAN,CECILIA PUI CHI CHIU,ANDREW PETERSON,DANIEL K. KIRCHHOFER,YAN WU,PAUL MORAN,WEI LI,XANTHE LAM,LIN LUIS,ADA HUI,WHITTEMORE TINGLEY,JOHN DOUGLAS DAVIS,NAGESHWAR R.
申请号：
ARP130102123
公开号：
AR091462A1
申请日:
2013.06.14
申请国别(地区):
AR
年份:
2015
代理人:
摘要：
Claim 1: An anti-PCSK9 antibody characterized in that it comprises a heavy chain and light chain variable domain comprising six hypervariable region (HVR) sequences: (i) HVR-H1 comprising GFTFX¹X²X³X⁴IH (SEQ ID No. 28),X1 is s or T； X2 is g, R or s； X3 is h, t or Y； x8308a is a or T； (II) hvr-h2, including rispangtnayadskg (SEQ ID No.4)；(III) hvr-h3, including wigreliyimdy (SEQ ID No.5)；(IV) hvr-l1 including rasqdvsx1 AVA (SEQ ID No.29),Where X1 is s or T； (V) hvr-l2, including sasx1 (SEQ ID No.30),where X¹ is F or S； and (vi) HVR-L3 comprising QQAYX¹X²X³X⁴T (SEQ ID No. 37),X1 is p, R or T； X2 is a, I, s or T； X3 is l, P or Q； x83080 is a, h, P or S. claim 17: a unique nucleic acid characterized by coding against PCSK9 antibodies according to any one claim 1 to 16. Claim 23: a method for obtaining anti PCSK9 antibody, characterized in that it includes culturing host cells under appropriate conditions in accordance with claim 20 to express nucleic acid used to encode anti PCSK9 antibody. Requirement 26: drug compositionAccording to any requirements of items 1-16 and 25, it includes anti PCSK9 antibody and is an acceptable pharmacist. Requirement 56: treatment of cholesterol related diseasesThis method is characterized by putting an effective amount of anti PCSK9 antibody into operation in accordance with any one of claims 1-16 and 25, or in accordance with any one of claims 26-50. Claim 94: a subcutaneous dose of anti PCSK9, 400 to 1000 mg every 4 weeks, 12 weeks or 3 months, characterized by the treatment of a person's high cholesterol.Reivindicación 1: Un anticuerpo anti-PCSK9 caracterizado porque comprende un dominio variable de la cadena pesada y la cadena liviana que comprende seis secuencias de la región hipervariable (HVR): (i) HVR-H1 que comprende GFTFX¹X²X³X⁴IH (SEQ ID Nº 28), donde X¹ es S o T； X² es G, R o S； X³ es H, T o Y； X⁴ es A o T； (ii) HVR-H2 que comprende RISPANGNTNYADSVKG (SEQ ID Nº 4)； (iii) HVR-H3 que comprende WIGSRELYIMDY (SEQ ID Nº 5)； (iv) H
